Alpha 2.0
Login Register
» Journals » IJTLD Open

Ijtld Open

Ijtld Open is a scientific journal, published since 2024 in English. The journal's country of origin is France.
Details
Abbr. IJTLD Open
Start 2024
End Continuing
Frequency Monthly
e-ISSN 3005-7590
Country France
Language English
Recent Articles
1.
Sustained treatment success at 12 months for drug-resistant TB patients on concomitant bedaquiline-delamanid
Chavan V, Silsarma A, Mahajan R, Khan S, Singh P, Iyer A, et al.
IJTLD Open . 2025 Feb; 2(2):107-109. PMID: 39959408
No abstract available.
2.
Assessing the accuracy of the updated Fujifilm SILVAMP TB LAM II assay between lot numbers
Chikamatsu K, Shimomura Y, Osugi A, Mitarai S
IJTLD Open . 2025 Feb; 2(2):96-100. PMID: 39959407
Background: The Fujifilm SILVAMP TB LAM (FujiLAM) assay, a point-of-care test detecting urine-based lipoarabinomannans, has demonstrated notable diagnostic accuracy for TB. However, FujiLAM exhibits lot-to-lot variability, limiting its clinical use....
3.
Comparative efficacy of tetracyclines against isolates of complex
Singh S, Boorgula G, Shrivastava A, Gumbo T, Srivastava S
IJTLD Open . 2025 Feb; 2(2):113-115. PMID: 39959406
No abstract available.
4.
Efficacy and safety data on pretomanid for drug-resistant TB
Thuy H, Padmapriyadarsini C, Chuchottaworn C, Foraida S, Hadigal S, Birajdar A
IJTLD Open . 2025 Feb; 2(2):73-82. PMID: 39959405
Objective: To summarise the efficacy and safety of pretomanid (Pa) based regimens in patients with drug-resistant TB (DR-TB). Methods: We included clinical trials, operational research and observational studies reporting the...
5.
Patient pathway analysis of rifampicin-resistant TB diagnostic and treatment delays
Ge S, Feng Z, Lin L, Li R, Zhang Y, Song L, et al.
IJTLD Open . 2025 Feb; 2(2):90-95. PMID: 39959404
Background: Barriers to the diagnosis and treatment of rifampicin-resistant TB (RR-TB) have not been fully elucidated. This study aimed to map the diagnostic and treatment delays among patients with RR-TB...
6.
Closing the gaps in childhood TB detection
Creswell J, Colvin C
IJTLD Open . 2025 Feb; 2(2):83-89. PMID: 39959403
Globally, the gap between the number of children who develop TB and those who are detected and treated is narrowing, but it remains much wider than among adults. Several new...
7.
Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe
Kirakosyan O, Reimann M, Andersen A, Bjarnason A, Bakos A, Dyrhol-Riise A, et al.
IJTLD Open . 2025 Feb; 2(2):101-106. PMID: 39959402
Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. Methods: Between November 2023 and...
8.
Rapidly progressive silicosis previously diagnosed as pulmonary TB in mineworkers
Pyana Kitenge J, Said-Hartley Q, Dubbeldam A, Kabeya Mulaji I, Kyansa Mangi P, Musa Obadia P, et al.
IJTLD Open . 2025 Feb; 2(2):110-112. PMID: 39959401
No abstract available.
9.
Ending the TB epidemic - what can we learn from the HIV epidemic?
Harries A
IJTLD Open . 2025 Feb; 2(2):61-63. PMID: 39959400
Advocates for community-wide screening promote this approach to reduce TB incidence and end the TB epidemic. The roll-out of antiretroviral therapy (ART) for HIV-infected people is often cited as evidence...
10.
The Western Pacific Regional Framework to End TB: overview and critical reflection
Oh K, Morishita F, Rahevar K, Yadav R, Tran H, Marks G, et al.
IJTLD Open . 2025 Feb; 2(2):64-72. PMID: 39959399
Despite notable progress, TB remains a critical public health challenge in the Western Pacific Region. To address this, the WHO developed the Western Pacific Regional Framework to End TB, which...